All In Biotech

Drug Trial Radar · NCT02858258

ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Autologous Transplantation After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma - a Randomized European Mcl Network Trial

Last checked: Nov 19, 2026Latest source record: Dec 19, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 870 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

870

Planned (sponsor's estimate)

Start

Jul 2016

Primary completion

May 2021

Study completion May 2026

Sponsor

Lead sponsor
Prof. Dr. M. Dreyling (co-chairman)Academic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
LMU Klinikum
First posted
Aug 8, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the the trial is to establish one of three study arms, as future standard based on the comparison of the investigator-assessed failure-free survival.

Conditions

  • Mantle Cell Lymphoma

Interventions

  • R-CHOP/R-DHAPDrug

    Drug: R-CHOP/DHAP Alternating 3x R-CHOP (Rituximab , Cyclophosphamide ,Doxorubicine ,Vincristine , Prednisone) / 3x R-DHAP (Rituximab , Dexamethasone, Ara-C, Cisplatine, G-CSF)

  • Ibrutinib (Induction)Drug

    Ibrutinib: only in cycle 1,3,5 on Day 1-19

  • ASCT conditioningDrug

    ASCT conditioning THAM or BEAM, stratified per site before trial activation at site THAM (TBI (total body irradiation), Ara-C, Melphalan) or BEAM (BCNU, Etoposide, Cytarabine, Melphalan)

  • Ibrutinib (Maintenance)Drug

    Ibrutinib (Maintenance), daily 560 mg for 2 years;

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Failure Free SurvivalTime frame: From start of treatment until stable disease at end of immuno-chemotherapy, progressive disease, or death from any cause, whichever comes first, assessed up to 120 months.

Locations

112 sites in 5 countries. Site status is shown where the registry gives one.

  • Aalborg University Hospital, Dept of Hematology

    Aalborg, Denmark · Not yet recruiting

  • Aarhus University Hospital, Dept of Hematology

    Aarhus C, Denmark · Not yet recruiting

  • Rigshospitalet, Clinic of Hematology

    Copenhagen, Denmark · Not yet recruiting

  • Herlev Hospital, Department of Hematology L121

    Herlev, Denmark · Not yet recruiting

  • Odense University Hospital, Dept of Hematology X

    Odense C, Denmark · Not yet recruiting

  • Sjaelland University Hospital, Dept of Hematology

    Roskilde, Denmark · Not yet recruiting

  • Zentralklinik Augsburg, II. Med. Klinik, Hämatologie int. Onkologie

    Augsburg, Germany · Recruiting

  • Onkologische Gemeinschaftspraxis Dr. Janssen/Dr. Reichert in der Ubbo-Emmius-Klinik

    Aurich, Germany · Recruiting

  • Klinikum Bayreuth, Klinik f. Onkologie und Hämatologie

    Bayreuth, Germany · Recruiting

  • Vivantes Klinikum Am Urban, Klinik f. Innere Medizin, Hämatologie und Onkologie

    Berlin, Germany · Recruiting

  • Charité Univ.-Medizin Berlin, Med. Klinik - Hämatologie, Onkologie und Tumorimmunologie

    Berlin, Germany · Not yet recruiting

  • Helios Klinikum Berlin-Buch, Hämatologie, Onkologie und Tumorimmunologie

    Berlin, Germany · Recruiting

  • Knappschaftskrankenhaus Bochum-Langendreer

    Bochum, Germany · Recruiting

  • Universitätsklinikum Bonn

    Bonn, Germany · Recruiting

  • Diako ev. Diakonie-KH gGmbH, Med. Klinik II, Hämatologie und Onkologie

    Bremen, Germany · Recruiting

  • Klinikum Chemnitz gGmbH, Klinik f. Innere Medizin II

    Chemnitz, Germany · Recruiting

  • Uniklinik Köln, Klinik I für Innere Medizin

    Cologne, Germany · Recruiting

  • DONAUISAR Klinikum Deggendorf, Innere Medizin II

    Deggendorf, Germany · Recruiting

  • St.-Johannes-Hospital

    Dortmund, Germany · Recruiting

  • Gemeinschaftspraxis Dr. Mohm und Prange-Krex - Fachärzte für Innere Medizin und Hämatologie und Onkologie

    Dresden, Germany · Recruiting

  • Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden

    Dresden, Germany · Recruiting

  • Universitätsklinikum Düsseldorf, Klinik f. Hämatologie, Onkologie und klinische Immunologie

    Düsseldorf, Germany · Recruiting

  • Marien Hospital Düsseldorf

    Düsseldorf, Germany · Recruiting

  • Helios Klinikum Erfurt GmbH, Zentrum f. Innere Medizin u. internistische Onkologie, Hämostaseologie

    Erfurt, Germany · Recruiting

  • Universitätsklinikum Erlangen, Med. Klinik 5, Hämatologie und internistische Onkologie

    Erlangen, Germany · Recruiting

  • St.-Antonius-Hospital Eschweiler, Klinik für Hämatologie und Onkologie

    Eschweiler, Germany · Recruiting

  • Universitätsklinikum Essen, Klinik f. Hämatologie

    Essen, Germany · Recruiting

  • Universitätsklinikum Freiburg, Klinik f. Innere Medizin, Hämatologie, Onkologie u. Stammzelltransplantation

    Freiburg im Breisgau, Germany · Recruiting

  • Universitätsmedizin Göttingen, Zentrum f. Innere Medizin, Klinik f. Hämatologie und Medizinische Onkologie

    Göttingen, Germany · Recruiting

  • Universitätsmedizin Greifswald, Klinik u. Poliklinik f. Innere Medizin C, Hämatologie u. Onkologie-, Transplantationszentrum

    Greifswald, Germany · Recruiting

  • Katholisches Krankenhaus Hagen gGmbH, St.-Marien-Hospital, Klinik f. Hämatologie und Onkologie

    Hagen, Germany · Recruiting

  • Universitätsklinikum Hamburg-Eppendorf (UKE), II. Med. Klinik u. Poliklinik, Onkologie, Hämatologie, KMT

    Hamburg, Germany · Recruiting

  • Asklepios Klinik Altona, II. Med.Abt. f. Hämatologie und internistische Onkologie, Stammzelltransplantation

    Hamburg, Germany · Recruiting

  • Universitätsklinikum Heidelberg, Med. Klinik - Innere Medizin V - Hämatologie, Onkologie und Rheumatologie

    Heidelberg, Germany · Recruiting

  • Universitätsklinikum des Saarlandes, Klinik f. Innere Medizin I Hämatologie & Onkologie

    Homburg, Germany · Recruiting

  • Klinikum Idar-Oberstein GmbH, Medizinische Klinik I

    Idar-Oberstein, Germany · Recruiting

  • Universitätsmedizin Jena, Klinik f. Innere Medizin II, Abteilung Hämatologie u. Internistische Onkologie

    Jena, Germany · Recruiting

  • Städtisches Klinikum Karlsruhe, Med. Klinik III, Hämatologie und Onkologie

    Karlsruhe, Germany · Recruiting

  • Universitätsklinikum Schleswig-Holstein, Campus Kiel, Klinik f. Innere Medizin II - Hämatologie und Onkologie

    Kiel, Germany · Recruiting

  • Gemeinschaftsklinikum Mittelrhein gGmbH, Ev. Stift St. Martin, Klinik f. Innere Medizin

    Koblenz, Germany · Recruiting

Showing 40 of 112 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.